Comparative Pharmacology
Head-to-head clinical analysis: ACIPHEX versus YOSPRALA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACIPHEX versus YOSPRALA.
ACIPHEX vs YOSPRALA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Yosprala is a combination of aspirin (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 and cyclooxygenase-2, thereby reducing thromboxane A2 synthesis and platelet aggregation) and omeprazole (a proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme in gastric parietal cells).
20 mg orally once daily; duration: 4-8 weeks for erosive esophagitis, 4 weeks for GERD, 24 weeks for H. pylori eradication (triple therapy: AcipHex 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for 7 days), 4 weeks for duodenal ulcer, up to 12 months for pathological hypersecretory conditions.
YOSPRALA (esomeprazole magnesium and naproxen) is available as delayed-release tablets containing 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole. The typical adult dose is one tablet twice daily, swallowed whole with liquid, at least 30 minutes before meals.
None Documented
None Documented
Plasma half-life 1-2 hours, but pharmacodynamic half-life (acid suppression) >24 hours due to accumulation in parietal cell canaliculi.
Naproxen: terminal elimination half-life is approximately 14 hours (range 12–17 hours), allowing twice-daily dosing. Esomeprazole: terminal half-life is approximately 1.2–1.5 hours after single dose, increasing to ~1.5–2.5 hours with repeated dosing due to saturation of CYP2C19. Clinical context: naproxen's half-life supports sustained analgesic/anti-inflammatory effect; esomeprazole's shorter half-life requires daily dosing for acid suppression.
Hepatic metabolism, primarily via CYP2C19 and CYP3A4; ~90% eliminated as metabolites in urine, <1% unchanged; remainder in feces.
YOSPRALA (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is primarily excreted in urine as unchanged drug (approximately 60%) and as glucuronide conjugates (approximately 30%). Esomeprazole is extensively metabolized; less than 1% of the dose is excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder via metabolites.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor